Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-6213 + atorvastatin
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-6213 + atorvastatin is an experimental oral combination therapy investigated for the treatment of hypercholesterolemia and related lipid disorders. MK-6213 is a small molecule inhibitor of Niemann-Pick C1-like protein 1 (NPC1L1), acting as a cholesterol absorption inhibitor, developed by Merck Sharp & Dohme. Atorvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor ("statin"), widely used for lowering cholesterol by inhibiting endogenous cholesterol synthesis. The combination was tested to achieve more substantial lipid-lowering effects than monotherapy, leveraging complementary mechanisms: inhibition of intestinal cholesterol absorption (MK-6213) and inhibition of hepatic cholesterol synthesis (atorvastatin).
- Other names
- MK-6213/atorvastatin
02
Targets
NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on MK-6213 + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-6213 + atorvastatin.